Headache News and Research

Latest Headache News and Research

Genzyme’s Mozobil approved in Europe

Genzyme Corporation announced today that the European Commission has granted marketing authorization for Mozobil ® (plerixafor injection), providing a significant new option for patients with the blood cancers lymphoma and multiple myeloma who require an autologous stem cell transplant.

6 Aug 2009

Tips to avoid heat stroke

The first sign of dangerous heat stroke can be just that – no sweat. As the temperature rises, your body’s natural cooling mechanism, sweat (or more kindly, perspiration), evaporates and helps to cool your body. But on those hot, humid cut-the-air-with-a knife days, evaporation is slowed and your body may not be able to keep itself cool.

5 Aug 2009

Neck surgery for cervical spine disorders alleviates headaches

A new study published in the August 2009 issue of the Journal of Bone and Joint Surgery (JBJS) finds that two years after anterior cervical neck operations, patients who have arthroplasty (disc replacement) or arthodesis (spine fusion) can be expected to have significant improvement in their headache symptoms.

3 Aug 2009

FDA approves Onglyza (saxagliptin) for type 2 diabetes

The U.S. Food and Drug Administration has approved Onglyza (saxagliptin), a once-daily tablet to treat Type 2 diabetes in adults. The medication is intended to be used with diet and exercise to control high blood sugar levels.

2 Aug 2009

Surgical treatment of migraine safe and effective

Migraine headaches are a drain - not only on the estimated 30 million Americans who suffer from them, but on the economy, too. Because pain and other symptoms caused by migraine headaches can be quite severe, it is projected that nearly $13 billion is spent every year in headache treatment and loss of time from work, which no one can afford these days.

31 Jul 2009

Hepatitis C infection: Treatment options equally effective, likelihood of success known early on

Results of a long-awaited study of 3,070 American adults at Johns Hopkins and 118 other U.S. medical centers show that treatment with either of the two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death.

22 Jul 2009

NDA for Exenatide once weekly accepted for FDA review

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration (FDA).

7 Jul 2009

Smoking provokes migraine attacks

Tobacco acts as a precipitating factor for headaches, specifically migraines. This is indicated in a study which shows that smokers have more migraine attacks and that smoking more than five cigarettes a day triggers this headache. The work has appeared in The Journal of Headache and Pain.

24 Jun 2009

Migraines with aura in middle age associated with late-life brain lesions

Women who suffer from migraine headaches in middle age accompanied by neurological aura (visual disturbances, dizziness or numbness that can precede migraines) are more likely to have damage to brain tissue in the cerebellum later in life, according to a study by researchers at the National Institute on Aging (NIA) of the National Institutes of Health, the Uniformed Services University of the Health Sciences and the Icelandic Heart Association in Reykjavik.

23 Jun 2009

FDA approves injectable Ibuprofen

The U.S. Food and Drug Administration today approved Caldolor, the first injectable dosage form of the common pain medication ibuprofen, to treat pain and fever.

11 Jun 2009

Novel diabetes treatment Syncria (albiglutide) improves glucose control and reduces weight

New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.

9 Jun 2009

Middle-aged women experience more stress but have lower blood pressure

The study is part of the Prospective Population Study of Women in Gothenburg, Sweden. This study was initiated at the end of the 1960s, when 1,462 middle-aged women were examined, and interviewed about their lifestyle and other matters.

5 Jun 2009

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

Reclast (zoledronic acid) Injection has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. Reclast is already approved as a once-yearly infusion for the treatment of postmenopausal osteoporosis.

1 Jun 2009

FDA approves Besivance as a treatment for bacterial conjunctivitis

The U.S. Food and Drug Administration today approved Besivance (besifloxacin ophthalmic suspension 0.6 percent) for the treatment of bacterial conjunctivitis (non-viral), a contagious condition marked by irritation of the eyes and a discharge from the mucous membranes.

28 May 2009

Second death from mosquito-borne disease prompts calls for more spraying programs

The recent death of a second person from Murray Valley Encephalitis (MVE) in Northern Australia has prompted calls for an increase in mosquito control spraying programs.

28 May 2009

Common migraine pain condition allodynia also prevalent in cluster headache

A pain condition common in people with migraines also has a high prevalence in patients with cluster headache, according to a study conducted by researchers at the Jefferson Headache Center at Jefferson Hospital for Neuroscience.

27 May 2009

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).

27 May 2009

The future of migraine: beyond just another pill

Patients living with migraine have strong reason for new optimism concerning a positive future. Two review articles and an accompanying editorial, "The Future of Migraine: Beyond Just Another Pill," in the current issue of Mayo Clinic Proceedings, are the basis for an ironic premise.

26 May 2009

FDA approves Samsca (tolvaptan) to treat hyponatremia

The U.S. Food and Drug Administration has approved Samsca tablets (tolvaptan) to treat hyponatremia, an abnormally low concentration of sodium in the blood.

22 May 2009

Cimzia approved in U.S. for rheumatoid arthritis

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

13 May 2009